UY29962A1 - Compuestos calciliticos - Google Patents
Compuestos calciliticosInfo
- Publication number
- UY29962A1 UY29962A1 UY29962A UY29962A UY29962A1 UY 29962 A1 UY29962 A1 UY 29962A1 UY 29962 A UY29962 A UY 29962A UY 29962 A UY29962 A UY 29962A UY 29962 A1 UY29962 A1 UY 29962A1
- Authority
- UY
- Uruguay
- Prior art keywords
- formula
- present
- animal
- receptor antagonists
- indicated below
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
- C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención comprende los antagonistas receptores del nuevo calcio representado por la Fórmula (I) y la Fórmula (II) indicada a continuación, formulaciones que comprenden los presentes compuestos y sus usos como antagonistas receptores del calcio en el tratamiento de una variedad de enfermedades asociadas con homeostasis ósea o mineral anómala, incluidos pero sin limitarse a =hipoparatiroidismo, osteosarcoma, enfermedad periodontal, curación de fractura, osteoartritis, artritis reumatoidea, enfermedad de Paget, hipercalcemia humoral asociada con malignidad y curación de fractura y osteoporosis. La presente invención provee además un método para aumentar el nivel del suero paratiroides en un animal, incluidos los humanos, los cuales comprenden administración a un animal con necesidad del mismo una cantidad efectiva de un compuesto de la Formula (I) o (II), indicada a continuación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73873105P | 2005-11-22 | 2005-11-22 | |
US73906705P | 2005-11-22 | 2005-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY29962A1 true UY29962A1 (es) | 2007-06-29 |
Family
ID=38068035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY29962A UY29962A1 (es) | 2005-11-22 | 2006-11-22 | Compuestos calciliticos |
Country Status (14)
Country | Link |
---|---|
US (1) | US20090137557A1 (es) |
EP (1) | EP1951244A4 (es) |
JP (1) | JP2009516756A (es) |
KR (1) | KR20080080136A (es) |
AR (1) | AR057625A1 (es) |
AU (1) | AU2006318275A1 (es) |
BR (1) | BRPI0618900A2 (es) |
CA (1) | CA2630117A1 (es) |
EA (1) | EA200801414A1 (es) |
IL (1) | IL191477A0 (es) |
MA (1) | MA30042B1 (es) |
TW (1) | TW200738649A (es) |
UY (1) | UY29962A1 (es) |
WO (1) | WO2007062370A2 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
MX2009011358A (es) * | 2007-04-20 | 2009-11-05 | Schering Corp | Derivados de pirimidinona y metodos para su uso. |
PE20091102A1 (es) | 2007-12-17 | 2009-07-25 | Janssen Pharmaceutica Nv | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 |
WO2010039913A1 (en) * | 2008-10-01 | 2010-04-08 | Glaxosmithkline Llc | Calcilytic compounds |
WO2010039922A1 (en) * | 2008-10-03 | 2010-04-08 | Glaxosmithkline Llc | Calcilytic compounds |
FR2937321B1 (fr) * | 2008-10-21 | 2010-10-22 | Rhodia Operations | Procede de fabrication de composes comprenant des fonctions nitriles |
US9498471B2 (en) | 2011-10-20 | 2016-11-22 | The Regents Of The University Of California | Use of CDK9 inhibitors to reduce cartilage degradation |
RU2701156C9 (ru) | 2012-07-18 | 2019-12-18 | Саншайн Лейк Фарма Ко., Лтд. | Азотсодержащие гетероциклические производные и их применение в фармацевтических препаратах |
GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
AU2013344422A1 (en) * | 2012-11-16 | 2015-07-02 | Biocryst Pharmaceuticals, Inc. | Antiviral azasugar-containing nucleosides |
JP6454348B2 (ja) | 2013-12-19 | 2019-01-16 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 窒素複素環誘導体およびその医薬品への応用 |
US10183949B2 (en) | 2014-08-29 | 2019-01-22 | The University Of Tokyo | Pyrimidinone derivative having autotaxin-inhibitory activity |
CN118184502B (zh) * | 2024-05-16 | 2024-08-16 | 济南悟通生物科技有限公司 | 一种制备藜芦酮的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1551812B1 (en) * | 2001-12-06 | 2009-03-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
AU2003291761A1 (en) * | 2002-11-04 | 2004-06-07 | Nps Pharmaceuticals, Inc. | Quinazolinone compounds as calcilytics |
WO2004092120A2 (en) * | 2003-04-07 | 2004-10-28 | Nps Pharmaceuticals, Inc. | Pyrimidinone compounds as calcilytics |
EP1697331A4 (en) * | 2003-12-19 | 2010-08-04 | Merck Sharp & Dohme | INHIBITORS OF MITOTIC KINESINE |
CA2549641A1 (en) * | 2003-12-19 | 2005-07-21 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
EP1742924A4 (en) * | 2004-05-06 | 2010-10-06 | Glaxosmithkline Llc | CALCILYTIC COMPOUNDS |
WO2006066070A2 (en) * | 2004-12-17 | 2006-06-22 | Nps Pharmaceuticals, Inc. | Prodrug constructs of pyrimidinone compounds as calcilytics |
-
2006
- 2006-11-21 TW TW095143033A patent/TW200738649A/zh unknown
- 2006-11-21 EA EA200801414A patent/EA200801414A1/xx unknown
- 2006-11-21 JP JP2008542512A patent/JP2009516756A/ja active Pending
- 2006-11-21 AU AU2006318275A patent/AU2006318275A1/en not_active Abandoned
- 2006-11-21 BR BRPI0618900-8A patent/BRPI0618900A2/pt not_active IP Right Cessation
- 2006-11-21 US US12/094,665 patent/US20090137557A1/en not_active Abandoned
- 2006-11-21 KR KR1020087014987A patent/KR20080080136A/ko not_active Application Discontinuation
- 2006-11-21 WO PCT/US2006/061150 patent/WO2007062370A2/en active Application Filing
- 2006-11-21 EP EP06839984A patent/EP1951244A4/en not_active Withdrawn
- 2006-11-21 CA CA002630117A patent/CA2630117A1/en not_active Abandoned
- 2006-11-22 AR ARP060105122A patent/AR057625A1/es not_active Application Discontinuation
- 2006-11-22 UY UY29962A patent/UY29962A1/es not_active Application Discontinuation
-
2008
- 2008-05-15 IL IL191477A patent/IL191477A0/en unknown
- 2008-06-11 MA MA31019A patent/MA30042B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
EP1951244A4 (en) | 2010-08-25 |
WO2007062370A3 (en) | 2007-11-22 |
MA30042B1 (fr) | 2008-12-01 |
CA2630117A1 (en) | 2007-05-31 |
IL191477A0 (en) | 2009-02-11 |
EP1951244A2 (en) | 2008-08-06 |
WO2007062370A2 (en) | 2007-05-31 |
AU2006318275A1 (en) | 2007-05-31 |
KR20080080136A (ko) | 2008-09-02 |
EA200801414A1 (ru) | 2008-10-30 |
AR057625A1 (es) | 2007-12-05 |
BRPI0618900A2 (pt) | 2011-09-27 |
TW200738649A (en) | 2007-10-16 |
US20090137557A1 (en) | 2009-05-28 |
JP2009516756A (ja) | 2009-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY29962A1 (es) | Compuestos calciliticos | |
UY30620A1 (es) | Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio | |
MX2021001752A (es) | Compuestos de pirrolo-dipiridina. | |
CY1121922T1 (el) | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης | |
CO6270312A2 (es) | Moduladores de gpr40 bifenilo-sustituidos | |
BRPI0409680A (pt) | análogos de fosfonato anti-cáncer | |
CY1118691T1 (el) | Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης | |
UY29004A1 (es) | Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso. | |
UY27154A1 (es) | Pirimidinas inhibidoras de metaloproteinasa de matriz | |
UY28473A1 (es) | Nuevos compuestos | |
CY1108105T1 (el) | Ιβανδρονικο οξυ για την θεραπευτικη αντιμετωπιση και την προληψη της οστεoπορωσης | |
HN2004000319A (es) | "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia" | |
BR0115696A (pt) | Uso de bisfosfonatos para tratamento de dor | |
EA201001286A1 (ru) | Комбинированное применение 25-гидроксивитамина d3 и витамина d3 для повышения плотности минерального вещества костей и для лечения остеопороза | |
EA201101475A1 (ru) | Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта | |
UY30723A1 (es) | Compuestos de biciclocarboxiamida sustituidos | |
UY29079A1 (es) | Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
EA200801261A1 (ru) | Фармацевтические композиции на основе галлия и способы | |
CL2004000868A1 (es) | Compuestos derivados de acidos carboxilicos, antagonistas del receptor de calcio 8casr); composiciones farmaceuticas que comprenden el compuesto, utiles para el tratamiento de osteoporosis. | |
PA8576101A1 (es) | Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso | |
EA201070893A1 (ru) | Способы и композиции для лечения заболеваний костей | |
PA8601001A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
CL2012000609A1 (es) | Compuestos derivados de indenona; composicion farmaceutica que los comprende, util para prevenir o tratar una enfermedad osea seleccionada de osteoporosis, desorden del crecimiento oseo, fracturas oseas, enfermedad periodontal, enfermedad de paget, carcinoma metastatico y artritis reumatoide. | |
AR064406A1 (es) | Compuesto de (halo-alquilcarboxi-fenil)-hidroxietilamina composicion farmaceutica que lo comprende su uso para preparar un medicamento, metodo para sintetizar dicho compuesto y compuesto intermedio correspondiente | |
MY121054A (en) | Calcilytic compounds as calcium receptor antagonists. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20210318 |